Press Release
Ivy Brain Tumor Center Launches New Clinical Trial For Recurrent Glioblastoma
The Ivy Brain Tumor Center at Barrow Neurological Institute announced that patient recruitment has opened for a Phase 0 clinical trial to evaluate two targeted therapy drugs, abemaciclib and LY3214996. The study will evaluate central nervous system (CNS) penetration in patients with recurrent glioblastoma scheduled for resection. This is the first time a combination of these two drugs will be tested in brain tumor patients.
Ivy Foundation Makes Multi-million Dollar Contribution To AZ Coronavirus Relief Fund
“It’s very important to me that the medical personnel in this state have the right tools and supplies to fight this battle,” said Catherine Ivy, co-founder of the Ivy Brain Tumor Center.
Ivy Brain Tumor Center Expands Phase 0 Clinical Trials Program to the East Valley
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced a partnership with two East Valley hospitals to expand its novel Phase 0 clinical trials program, the first of its kind in neuro-oncology.
Ivy Brain Tumor Center and SonALAsense to Test Novel Drug-Device Combination for Glioblastoma
The Ivy Brain Tumor Center at the Barrow Neurological Institute, today announced a strategic collaboration with SonALASense to develop and test a new, non-invasive drug-device combination, sonodynamic therapy (SDT), for recurrent glioblastoma through a Phase 0/2 clinical trial.
Ivy Brain Tumor Center And BridgeBio Subsidiary QED Therapeutics Announce Collaboration To Advance Cancer Research And Treatment Options
The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma, Inc., to investigate the FGFR1-3 tyrosine kinase inhibitor, infigratinib, for the treatment of glioblastoma (GBM).
Ivy Brain Tumor Center And Salarius Pharmaceuticals Launch Collaborative Partnership To Develop New Cancer Treatment For Glioblastoma
The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat, for the treatment of glioblastoma.
Glioblastoma Awareness Day Campaign Raises More Than $530K
Barrow Neurological Foundation led a fundraising effort that raised more than $539,000 for brain cancer research at the Ivy Brain Tumor Center on the first ever Glioblastoma Awareness Day, July 17, 2019.
Clinical Trial Identifies New Breast Cancer Drug As A Potential Therapy For Glioblastoma
The Ivy Brain Tumor Center at the Barrow Neurological Institute has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali®) for the treatment of recurrent glioblastoma.
Ivy Brain Tumor Center And Karyopharm Therapeutics Collaborate To Develop Tissue-Based Clinical Trial For Brain Cancer
The Ivy Brain Tumor Center at the Barrow Neurological Institute has announced a partnership with Karyopharm Therapeutics (Nasdaq:KPTI) to accelerate the treatment of brain cancer.
New Study Makes Important Step Toward Treatment Of Deadly Brain Cancer
A new Ivy Brain Tumor Center study finds that recently-approved drug ribociclib may be an important part of treatment for glioblastoma, one of the deadliest cancers in the world.